Pedroza Diego A, Ramirez Matthew, Rajamanickam Venkatesh, Subramani Ramadevi, Margolis Victoria, Gurbuz Tugba, Estrada Adriana, Lakshmanaswamy Rajkumar
Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States.
Front Oncol. 2021 Jul 19;11:710337. doi: 10.3389/fonc.2021.710337. eCollection 2021.
Increased expression of the progesterone receptor membrane component 1, a heme and progesterone binding protein, is frequently found in triple negative breast cancer tissue. The basis for the expression of PGRMC1 and its regulation on cellular signaling mechanisms remain largely unknown. Therefore, we aim to study microRNAs that target selective genes and mechanisms that are regulated by PGRMC1 in TNBCs.
To identify altered miRNAs, whole human miRNome profiling was performed following AG-205 treatment and PGRMC1 silencing. Network analysis identified miRNA target genes while KEGG, REACTOME and Gene ontology were used to explore altered signaling pathways, biological processes, and molecular functions.
KEGG term pathway analysis revealed that upregulated miRNAs target specific genes that are involved in signaling pathways that play a major role in carcinogenesis. While multiple downregulated miRNAs are known oncogenes and have been previously demonstrated to be overexpressed in a variety of cancers. Overlapping miRNA target genes associated with KEGG term pathways were identified and overexpression/amplification of these genes was observed in invasive breast carcinoma tissue from TCGA. Further, the top two genes ( and ) which are highly genetically altered are also associated with poorer overall survival.
Thus, our data demonstrates that therapeutic targeting of PGRMC1 in aggressive breast cancers leads to the activation of miRNAs that target overexpressed genes and deactivation of miRNAs that have oncogenic potential.
孕激素受体膜成分1(一种血红素和孕激素结合蛋白)的表达增加在三阴性乳腺癌组织中经常被发现。孕激素受体膜成分1(PGRMC1)表达的基础及其对细胞信号传导机制的调节在很大程度上仍然未知。因此,我们旨在研究在三阴性乳腺癌中靶向选择性基因的微小RNA以及受PGRMC1调节的机制。
为了鉴定改变的微小RNA,在AG - 205处理和PGRMC1沉默后进行了全人类微小RNA组分析。网络分析确定了微小RNA靶基因,同时使用KEGG、REACTOME和基因本体论来探索改变的信号通路、生物学过程和分子功能。
KEGG术语通路分析显示,上调的微小RNA靶向参与在致癌过程中起主要作用的信号通路的特定基因。而多个下调的微小RNA是已知的癌基因,并且先前已证明在多种癌症中过表达。鉴定了与KEGG术语通路相关的重叠微小RNA靶基因,并在来自TCGA的浸润性乳腺癌组织中观察到这些基因的过表达/扩增。此外,高度遗传改变的前两个基因(和)也与较差的总生存期相关。
因此,我们的数据表明,在侵袭性乳腺癌中对PGRMC1进行治疗性靶向会导致靶向过表达基因的微小RNA的激活以及具有致癌潜力的微小RNA的失活。